Bradycardia is having a heart rate of <60 beats/minute that may not affect the hemodynamic status of some patients.
A heart rate that is inadequate for the patient's current condition and may not be able to support life is a clinically significant bradycardia.

Bradycardia can be caused by problems in the sinoatrial node, problems in the conduction pathways of the heart, metabolic problems or heart attack/disease that caused damage to the heart.

The different types of bradycardia are sinus bradycardia, sick sinus syndrome, tachycardia-bradycardia syndrome, hypersensitive carotid sinus syndrome, sinus pause/arrest, sinoatrial node exit block and atrioventricular block.

Principles of Therapy

  • Management of sinus bradycardia is not necessary unless with inadequate cardiac output and/or with life-threatening arrhythmia
  • Observation & monitoring is recommended for hemodynamically stable patients
  • Second-line therapy and transcutaneous pacing may be considered only when a patient with acute symptomatic bradycardia is unresponsive to Atropine


1st-Line Agent


  • Used for symptomatic sinus bradycardia, hypersensitive carotid sinus syndrome, and atrioventricular (AV) blocks
  • Reverses cholinergic-mediated decrease in heart rate by exerting its parasympathomimetic effect on the myocardium
  • Improves signs and symptoms and cardiac rate
  • Use cautiously in patients with acute myocardial infarction or acute coronary ischemia
  • May not be effective in patients who have undergone cardiac transplantation
  • Temporizing measure for pending transcutaneous pacing
  • Prepare for transcutaneous pacing if symptomatic bradycardia does not improve after Atropine administration

2nd-Line Agents

  • Consider in patients with unsatisfactory response to Atropine and as temporizing measure while awaiting pacemaker insertion


  • Epinephrine infusion may be used in patients with symptomatic bradycardia, especially associated with hypotension, in whom Atropine may be inappropriate or after Atropine & transcutaneous pacing fails


  • May be used in patients with symptomatic bradycardia, especially associated with hypotension, in whom Atropine may be inappropriate or after Atropine fails
  • Dopamine infusion may be given in addition to Epinephrine or may be administered alone
  • Has both alpha & beta adrenergic agonist actions


  • Consider if the potential cause for bradycardia is overdose of a beta-blocker or Calcium channel antagonist

Isoproterenol (Isoprenaline)

  • May be considered for transient heart block but should be used with utmost caution
    • Not to be used in patients with acute MI
  • Increases heart rate or AV-nodal conduction in patients with acute symptomatic bradyarrhythmia

Other Agents:

  • Aminophylline, Theophylline, Glycopyrrolate, Terbutaline

Device-Based Therapies

  • Indication is determined by severity of bradycardia
  • Recommended for patients with symptomatic sinus bradycardia, atrioventricular (AV) block, hypersensitive carotid sinus syndrome
  • May be considered for patients at risk of asystole, hemodynamically unstable, & those unresponsive to Atropine
    • Also in patients ≥40 years old with recurrent unpredictable reflex syncope &/or documented symptomatic pauses due to sinus arrest or atrioventricular (AV) block, patients w/ history of syncope with asymptomatic pauses of >6 seconds secondary to sinus arrest, sinoatrial (SA) block, or atrioventricular (AV) block

Temporary Pacing

  • Emergency intervention used during the interval prior to permanent pacemaker implantation or resolution of bradycardia

Transcutaneous Pacing

  • Non-invasive intervention applicable for symptomatic bradycardias
  • Recommended for patients who fail to respond to Atropine therapy or if hemodynamically unstable especially those with high-degree atrioventricular (AV) blocks
  • Hemodynamic stability & ECG results should be monitored during pacing

Transvenous Pacing

  • Invasive intervention involving the insertion of a temporary pacemaker wire to acquire venous access into the thoracic region
    • Most common insertion sites are the internal jugular vein & subclavian vein
  • Performed if Atropine therapy & transcutaneous pacing fails
  • Should only be used in patients with high degree atrioventricular (AV) block without escape rhythm, & life-threatening bradyarrhythmias

Permanent Pacemaker Implantation

  • Prevents recurrence of syncope, improves symptoms, & increases survival rates
  • Indications include:
    • Symptomatic sinus bradycardia
    • Symptomatic patients with atrioventricular (AV) block
      • Patients with intermittent or paroxysmal intrinsic 2nd-3rd degree atrioventricular (AV) block
      • Patients with type I 2nd degree atrioventricular (AV) block should be symptomatic if being considered
      • Patient with type II 2nd degree  atrioventricular (AV) block with wide QRS interval should be considered regardless if symptomatic or not
    • Symptomatic sinus node dysfunction with heart rate <40 bpm
    • Patients with sinus node dysfunction without symptoms but with heart rate of <40 bpm
    • Patients with unexplained syncope with abnormal findings in EPS
    • Patients with recurrent syncope accompanied by ventricular asystole of >3 seconds due to spontaneously occurring carotid sinus stimulation & pressure
  • Also recommended for acute myocardial infarction (MI) patients with atrioventricular (AV) block, congenital atrioventricular (AV) block, & atrioventricular (AV) block associated with enhanced vagal tone
  • May be considered in patients with neuromuscular diseases ie myotonic muscular dystrophy, Erb dystrophy, peroneal muscular atrophy with bifascicular block or any fascicular block, regardless if with symptoms or not
  • Should be excluded if bradycardia is due to reversible causes, asymptomatic 1st degree AV block, asymptomatic 2nd degree Mobitz I with supra-Hisian conduction block, or atrioventricular (AV) block expected to resolve

Modes of Pacing:

  • Single chamber pacemaker is considered for patients needing a single-lead atrial sensing ventricular pacemaker
  • Dual chamber pacing is beneficial for patients with history of stroke, embolism, atrial fibrillation, reduced exercise capacity, pacemaker syndrome compared to single chamber pacing but with more complications recorded
  • Dual chamber pacemaker is preferred for patients with sinus node disease, acquired atrioventricular (AV) block when rate response is desired
    • Reduces risk of atrial fibrillation, stroke, pacemaker syndrome & improves overall quality of life
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
10 Mar 2018
Compared to triple therapy, dual antithrombotic therapy yields reduced bleeding without excess ischaemic and thromboembolic cardiac events in patients with long-term indication to chronic oral anticoagulation following percutaneous coronary intervention, according to a new study.
Roshini Claire Anthony, 4 days ago

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 3 days ago
Pearl Toh spoke with Dr Andrew Kates, vice chair of ACC.18 Scientific Session about what’s new in cardiology and what ACC.18 has to offer.
4 days ago
Slideshow: Highlights from the American College of Cardiology 67th Annual Scientific Session (ACC)